Cue Biopharma Inc (CUE)

$0.82 -0.01 (-0.87%)
Market Cap 63.48M
Revenue (ttm) 9.29M
Net Income (ttm) -40.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -437.78%
Debt to Equity Ratio 0.51
Volume 87,300
Avg Vol 354,438
Day's Range N/A - N/A
Shares Out 76.85M
Stochastic %K 59%
Beta 1.53
Analysts Strong Sell
Price Target $4.00

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2680
Address:
40 Guest Street, Boston, United States
d_risk
d_risk Aug. 13 at 5:34 AM
$CUE - Cue Biopharma, Inc. - 10Q - Updated Risk Factors No substantial changes in risk factor headings; CUE highlights ongoing going concern doubts, expanded U.S. trade policy and tariff risks, new tax law impacts, and Nasdaq listing compliance challenges with potential delisting. #Biopharma #NasdaqCompliance #TariffRisks #TradePolicy #GoingConcern 🟢 Added 🟠 Removed https://d-risk.ai/CUE/10-Q/2025-08-12
0 · Reply
CatCapital_ai
CatCapital_ai Aug. 12 at 8:07 PM
$CUE Earnings - Q2/2025 Revenue: $2.95M ✅ vs. $2.4M est. EPS: $(0.09) ✅ vs. $(0.14) est. Cue Biopharma advances IND plans for CUE-401 after FDA feedback, reports promising Phase 1b data for CUE-101 in HPV+ head and neck cancer, and collaborates with Boehringer Ingelheim on CUE-501. Raised $20M in Q2 to support ongoing autoimmune and cancer programs.
0 · Reply
ES33
ES33 Aug. 10 at 2:14 AM
$CUE it looks like the stock’s closing price has been below $1 since late March. Shouldn’t they have gotten a deficiency notice from Nasdaq? I understand that if they get a notice they have 6 months to regain compliance plus an option for another 6 months extension?
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 1:08 AM
$CUE Great piece that accurately captures CUE's current position. So if you want to refresh your understanding of CUE or learn about CUE for the first time, this is essential reading. https://beyondspx.com/article/cue-biopharma-precision-immunotherapy-platform-pivots-towards-partnerships-amidst-financial-headwinds-nasdaq-cue
1 · Reply
Ralphbeach
Ralphbeach Jul. 26 at 12:37 AM
$CUE Cue Biopharma, in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and support from LG Chem, Ltd., Seoul, South Korea. Is the Alligator in the sewer still trolling?
0 · Reply
stockinfocuz_
stockinfocuz_ Jul. 24 at 6:11 PM
$ONCY), Cue Biopharma, Inc. (NASDAQ: $CUE), Verastem, Inc. (NASDAQ: $VSTM), Allogene Therapeutics, Inc. (NASDAQ: $ALLO), and Perspective Therapeutics, Inc. (NYSE-American: $CATX).
0 · Reply
inno56
inno56 Jul. 22 at 10:49 PM
$CUE @LouBasenese Any comments regarding the news from last week? Is this one finally turning the corner?
0 · Reply
Smittysixty
Smittysixty Jul. 21 at 4:11 PM
When you see $PPBT thrown into lists alongside $ALXO $JANX $CUE $HOWL, that’s not analysis—it’s camouflage. It’s a tactic to normalize the price rise by anchoring it to other names with far earlier pipelines, higher burn rates, and limited data. 💥 Purple Biotech stands alone: • Phase 2 survival data in pancreatic cancer shows up to 90% death risk reduction in biomarker-selected patients. • CAPTN-3 platform is a tri-specific antibody engaging both T cells and NK cells. Solid tumor innovation with dual immune activation. • Cash runway to 2026, focused pipeline, expanding IP, and a strategy that’s quietly creating asymmetrical upside. These drugs remains grossly undervalued vs. peers still in Phase 1 or chasing crowded targets. Don’t let ticker bundling blur the signal. This biotech isn’t rising with the tide—it’s cutting through it. 🧬👊
1 · Reply
ThisWi11hurt
ThisWi11hurt Jul. 21 at 1:46 PM
$PPBT keeping it real I don’t get too into the nitty gritty of the methods of action etc. but Grok tells me PPBT is in the same class as $ALXO $JANX $CUE $HOWL. All of these stocks, PPBT included are drifting up ready for breakouts. Cancer funding announcements are about to come out I can feel it
1 · Reply
Invest2live
Invest2live Jul. 20 at 9:42 PM
$CUE 43% already; congrats 🎈👏🎊🌿 Checkout $ASRT
0 · Reply
Latest News on CUE
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 13, 2025, 8:00 AM EDT - 5 days ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 12, 2025, 4:05 PM EDT - 6 days ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 16, 2025, 8:00 AM EDT - 4 weeks ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jul 1, 2025, 4:05 PM EDT - 6 weeks ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Jun 24, 2025, 4:48 PM EDT - 7 weeks ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 12, 2025, 4:05 PM EDT - 3 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 8, 2025, 8:00 AM EDT - 3 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

May 5, 2025, 10:00 AM EDT - 3 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 6:12 PM EDT - 4 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 15, 2025, 2:00 AM EDT - 4 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 10:23 PM EDT - 4 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Apr 14, 2025, 5:05 PM EDT - 4 months ago

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma to Host Business Update Call and Webcast

Apr 14, 2025, 5:02 PM EDT - 4 months ago

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 31, 2025, 4:20 PM EDT - 5 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2024, 4:30 PM EST - 9 months ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 8:00 AM EST - 9 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 4:05 PM EST - 9 months ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma Announces Strategic Organizational Transition

Nov 14, 2024, 8:00 AM EST - 9 months ago

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Nov 8, 2024, 1:30 PM EST - 10 months ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 11 months ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:26 PM EDT - 11 months ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Sep 26, 2024, 11:10 PM EDT - 11 months ago

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 22, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 11, 2023, 3:32 PM EST - 1 year ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 7, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Cue Biopharma to Host Investor Call

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 11:00 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Cue Biopharma to Host Business Update Call and Webcast

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Mar 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Feb 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Feb 16, 2023, 10:30 AM EST - 2 years ago

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

d_risk
d_risk Aug. 13 at 5:34 AM
$CUE - Cue Biopharma, Inc. - 10Q - Updated Risk Factors No substantial changes in risk factor headings; CUE highlights ongoing going concern doubts, expanded U.S. trade policy and tariff risks, new tax law impacts, and Nasdaq listing compliance challenges with potential delisting. #Biopharma #NasdaqCompliance #TariffRisks #TradePolicy #GoingConcern 🟢 Added 🟠 Removed https://d-risk.ai/CUE/10-Q/2025-08-12
0 · Reply
CatCapital_ai
CatCapital_ai Aug. 12 at 8:07 PM
$CUE Earnings - Q2/2025 Revenue: $2.95M ✅ vs. $2.4M est. EPS: $(0.09) ✅ vs. $(0.14) est. Cue Biopharma advances IND plans for CUE-401 after FDA feedback, reports promising Phase 1b data for CUE-101 in HPV+ head and neck cancer, and collaborates with Boehringer Ingelheim on CUE-501. Raised $20M in Q2 to support ongoing autoimmune and cancer programs.
0 · Reply
ES33
ES33 Aug. 10 at 2:14 AM
$CUE it looks like the stock’s closing price has been below $1 since late March. Shouldn’t they have gotten a deficiency notice from Nasdaq? I understand that if they get a notice they have 6 months to regain compliance plus an option for another 6 months extension?
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 1:08 AM
$CUE Great piece that accurately captures CUE's current position. So if you want to refresh your understanding of CUE or learn about CUE for the first time, this is essential reading. https://beyondspx.com/article/cue-biopharma-precision-immunotherapy-platform-pivots-towards-partnerships-amidst-financial-headwinds-nasdaq-cue
1 · Reply
Ralphbeach
Ralphbeach Jul. 26 at 12:37 AM
$CUE Cue Biopharma, in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and support from LG Chem, Ltd., Seoul, South Korea. Is the Alligator in the sewer still trolling?
0 · Reply
stockinfocuz_
stockinfocuz_ Jul. 24 at 6:11 PM
$ONCY), Cue Biopharma, Inc. (NASDAQ: $CUE), Verastem, Inc. (NASDAQ: $VSTM), Allogene Therapeutics, Inc. (NASDAQ: $ALLO), and Perspective Therapeutics, Inc. (NYSE-American: $CATX).
0 · Reply
inno56
inno56 Jul. 22 at 10:49 PM
$CUE @LouBasenese Any comments regarding the news from last week? Is this one finally turning the corner?
0 · Reply
Smittysixty
Smittysixty Jul. 21 at 4:11 PM
When you see $PPBT thrown into lists alongside $ALXO $JANX $CUE $HOWL, that’s not analysis—it’s camouflage. It’s a tactic to normalize the price rise by anchoring it to other names with far earlier pipelines, higher burn rates, and limited data. 💥 Purple Biotech stands alone: • Phase 2 survival data in pancreatic cancer shows up to 90% death risk reduction in biomarker-selected patients. • CAPTN-3 platform is a tri-specific antibody engaging both T cells and NK cells. Solid tumor innovation with dual immune activation. • Cash runway to 2026, focused pipeline, expanding IP, and a strategy that’s quietly creating asymmetrical upside. These drugs remains grossly undervalued vs. peers still in Phase 1 or chasing crowded targets. Don’t let ticker bundling blur the signal. This biotech isn’t rising with the tide—it’s cutting through it. 🧬👊
1 · Reply
ThisWi11hurt
ThisWi11hurt Jul. 21 at 1:46 PM
$PPBT keeping it real I don’t get too into the nitty gritty of the methods of action etc. but Grok tells me PPBT is in the same class as $ALXO $JANX $CUE $HOWL. All of these stocks, PPBT included are drifting up ready for breakouts. Cancer funding announcements are about to come out I can feel it
1 · Reply
Invest2live
Invest2live Jul. 20 at 9:42 PM
$CUE 43% already; congrats 🎈👏🎊🌿 Checkout $ASRT
0 · Reply
Sanvangonza1
Sanvangonza1 Jul. 18 at 5:22 PM
$WGRX $CUE looking primed 👀
0 · Reply
Relee187200
Relee187200 Jul. 17 at 6:17 PM
$CUE Why isn’t cue skyrocketing??
1 · Reply
StockScanners
StockScanners Jul. 17 at 1:34 AM
$CUE Keep watch if this holds above .85
0 · Reply
GlynnBusson
GlynnBusson Jul. 17 at 12:56 AM
$CUE only need another 1400% to break even 😂
1 · Reply
MGeronimo
MGeronimo Jul. 16 at 8:17 PM
$CUE IN AT .87 5x NORMAL BUYING
1 · Reply
TotalAmateur
TotalAmateur Jul. 16 at 7:17 PM
$CUE mOS 32 mos (and counting) vs 12.3
0 · Reply
Invest2live
Invest2live Jul. 16 at 5:51 PM
$BDTX 21% already; congrats 🎈🎊🎉🌿 Check out $CUE and $LCTX and $TTD
1 · Reply
LewisDaKat
LewisDaKat Jul. 16 at 4:55 PM
News Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer https://marketwirenews.com/news-releases/cue-biopharma-reports-new-complete-response-and-conf-7897455408247626.html $CUE
0 · Reply
DARKP00L
DARKP00L Jul. 16 at 4:50 PM
$CUE 12:29 on Jul. 16 2025 Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer #tradeideas
0 · Reply
Invest2live
Invest2live Jul. 16 at 4:43 PM
$CUE 43% already; congrats 🎈🎊🎉🌿 Check out $TLRY and $NOTE
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:42 PM
$CUE well im out had to break even GL
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:36 PM
$CUE That’s what I was thinking after looking into it but idk much bout it! Gl
0 · Reply